{"DataElement":{"publicId":"13751695","version":"1","preferredName":"Modified Toxicity Criteria Fatigue Condition Grade","preferredDefinition":"A description of the modified toxicity criteria for fatigue grade.","longName":"13751659v1.00:13751668v1.00","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"13751659","version":"1","preferredName":"National Marrow Donor Program Modified Toxicity Criteria Fatigue Condition","preferredDefinition":"Criteria established by the National Marrow Donor Program (NMDP) that assesses potential toxicities following peripheral blood or bone marrow stem cell collection from donors and includes: fever in absence of infections; fatigue; rashes; injection site reaction; nausea; vomiting; loss of appetite; inability to sleep; dizziness, vertigo, or lightheadedness; fainting; and pain.:Overall tiredness and lack of energy._A state of being, such as a state of health.","longName":"13751560v1.00:13751658v1.00","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"13751560","version":"1","preferredName":"National Marrow Donor Program Modified Toxicity Criteria","preferredDefinition":"Criteria established by the National Marrow Donor Program (NMDP) that assesses potential toxicities following peripheral blood or bone marrow stem cell collection from donors and includes: fever in absence of infections; fatigue; rashes; injection site reaction; nausea; vomiting; loss of appetite; inability to sleep; dizziness, vertigo, or lightheadedness; fainting; and pain.","longName":"C199478","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"National Marrow Donor Program Modified Toxicity Criteria","conceptCode":"C199478","definition":"Criteria established by the National Marrow Donor Program (NMDP) that assesses potential toxicities following peripheral blood or bone marrow stem cell collection from donors and includes: fever in absence of infections; fatigue; rashes; injection site reaction; nausea; vomiting; loss of appetite; inability to sleep; dizziness, vertigo, or lightheadedness; fainting; and pain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCED37C0-8F10-1878-E053-731AD00AD0C4","latestVersionIndicator":"Yes","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-05-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"13751658","version":"1","preferredName":"Fatigue Condition","preferredDefinition":"Overall tiredness and lack of energy._A state of being, such as a state of health.","longName":"C3036:C25457","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fatigue","conceptCode":"C3036","definition":"Overall tiredness and lack of energy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Condition","conceptCode":"C25457","definition":"A state of being, such as a state of health.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCED9051-869C-2755-E053-731AD00A5975","latestVersionIndicator":"Yes","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-05-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCED9051-869D-2755-E053-731AD00A5975","latestVersionIndicator":"Yes","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-07-06","changeDescription":null,"administrativeNotes":"2023.7.6 Released per review. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"13751668","version":"1","preferredName":"National Marrow Donor Program Modified Toxicity Criteria Fatigue Grade","preferredDefinition":"Criteria established by the National Marrow Donor Program (NMDP) that assesses potential toxicities following peripheral blood or bone marrow stem cell collection from donors and includes: fever in absence of infections; fatigue; rashes; injection site reaction; nausea; vomiting; loss of appetite; inability to sleep; dizziness, vertigo, or lightheadedness; fainting; and pain._Overall tiredness and lack of energy._A position on a scale of intensity or amount or quality.","longName":"13751668v1.00","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"120","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"None","valueDescription":null,"ValueMeaning":{"publicId":"13707077","version":"1","preferredName":"None","longName":"13707077v1.00","preferredDefinition":"None (grade 0)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC997DFD-C173-2136-E053-731AD00AF445","latestVersionIndicator":"Yes","beginDate":"2023-05-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-26","modifiedBy":"KUMMEROA","dateModified":"2023-05-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FCEDAF56-34A8-2B5E-E053-731AD00A7E39","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-05-30","deletedIndicator":"No"},{"value":"Mild fatigue over baseline","valueDescription":null,"ValueMeaning":{"publicId":"13751691","version":"1","preferredName":"Mild fatigue over baseline","longName":"13751691v1.00","preferredDefinition":"Mild fatigue over baseline (grade 1)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCEDAF56-34A5-2B5E-E053-731AD00A7E39","latestVersionIndicator":"Yes","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-05-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FCEDAF56-34A9-2B5E-E053-731AD00A7E39","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-05-30","deletedIndicator":"No"},{"value":"Moderate or causing difficulty performing some ADL","valueDescription":null,"ValueMeaning":{"publicId":"13751692","version":"1","preferredName":"Moderate or causing difficulty performing some ADL","longName":"13751692v1.00","preferredDefinition":"Moderate or causing difficulty performing some ADL (grade 2)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCEDAF56-34A6-2B5E-E053-731AD00A7E39","latestVersionIndicator":"Yes","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-05-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FCEDAF56-34AA-2B5E-E053-731AD00A7E39","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-05-30","deletedIndicator":"No"},{"value":"Severe fatigue interfering with ADL","valueDescription":null,"ValueMeaning":{"publicId":"13751693","version":"1","preferredName":"Severe fatigue interfering with ADL","longName":"13751693v1.00","preferredDefinition":"Severe fatigue interfering with ADL (grade 3)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCEDAF56-34A7-2B5E-E053-731AD00A7E39","latestVersionIndicator":"Yes","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-05-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FCEDAF56-34AB-2B5E-E053-731AD00A7E39","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-05-30","deletedIndicator":"No"},{"value":"Disabling","valueDescription":null,"ValueMeaning":{"publicId":"13707081","version":"1","preferredName":"Disabling","longName":"13707081v1.00","preferredDefinition":"Disabling (grade 4)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC997DFD-C177-2136-E053-731AD00AF445","latestVersionIndicator":"Yes","beginDate":"2023-05-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-26","modifiedBy":"KUMMEROA","dateModified":"2023-05-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FCEDAF56-34AC-2B5E-E053-731AD00A7E39","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-05-30","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"13751697","version":"1","preferredName":"National Marrow Donor Program Modified Toxicity Criteria Fatigue Grade","preferredDefinition":"Criteria established by the National Marrow Donor Program (NMDP) that assesses potential toxicities following peripheral blood or bone marrow stem cell collection from donors and includes: fever in absence of infections; fatigue; rashes; injection site reaction; nausea; vomiting; loss of appetite; inability to sleep; dizziness, vertigo, or lightheadedness; fainting; and pain._Overall tiredness and lack of energy._A position on a scale of intensity or amount or quality.","longName":"13751697v1.00","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"National Marrow Donor Program Modified Toxicity Criteria","conceptCode":"C199478","definition":"Criteria established by the National Marrow Donor Program (NMDP) that assesses potential toxicities following peripheral blood or bone marrow stem cell collection from donors and includes: fever in absence of infections; fatigue; rashes; injection site reaction; nausea; vomiting; loss of appetite; inability to sleep; dizziness, vertigo, or lightheadedness; fainting; and pain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Fatigue","conceptCode":"C3036","definition":"Overall tiredness and lack of energy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Grade","conceptCode":"C48309","definition":"A position on a scale of intensity or amount or quality.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCEDD6F6-4364-3024-E053-731AD00A5D9C","latestVersionIndicator":"Yes","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-05-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCED9A97-846C-287F-E053-731AD00AD9B7","latestVersionIndicator":"Yes","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-07-06","changeDescription":null,"administrativeNotes":"2023.7.6 Released per review. ak2023.5.30 Created per ticket request CADSR0002455. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"What was the modified toxicity criteria for fatigue grade?","url":null,"context":"NHLBI"},{"name":"NMDP Text 1","type":"Application Standard Question Text","description":"Fatigue","url":null,"context":"NHLBI"},{"name":"NMDP Text 2","type":"Alternate Question Text","description":"Fatigue (lethargy, malaise, asthenia)","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCEDBC3E-1535-2CB3-E053-731AD00ABCD4","latestVersionIndicator":"Yes","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-07-06","changeDescription":null,"administrativeNotes":"2023.7.6 Released per review. ak","unresolvedIssues":null,"deletedIndicator":"No"}}